Pirow Bekker Selected Research

avacopan

2/2024	Pharmacokinetic Evaluation of the CYP3A4 and CYP2C9 Drug-Drug Interaction of Avacopan in 2 Open-Label Studies in Healthy Participants.
8/2023	The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial.
7/2023	The Glucocorticoid Toxicity Index-Metabolic Domains, an abridged version of the Glucocorticoid Toxicity Index: post-hoc analysis of data from the ADVOCATE trial.
4/2023	Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan.
3/2023	Glucocorticoid Toxicity Index scores by domain in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with avacopan versus standard prednisone taper: post-hoc analysis of data from the ADVOCATE trial.
5/2022	C5a receptor inhibitor avacopan in immunoglobulin A nephropathy-an open-label pilot study.
1/2021	Avacopan for the Treatment of ANCA-Associated Vasculitis.
1/2021	Avacopan for the Treatment of ANCA-Associated Vasculitis. Reply.
11/2020	Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
4/2020	Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pirow Bekker Research Topics

Disease

12	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis 02/2024 - 09/2017
8	Vasculitis (Vasculitides) 08/2023 - 09/2017
3	Inflammation (Inflammations) 08/2023 - 10/2010
2	Infections 03/2023 - 05/2004
2	Proteinuria 05/2022 - 09/2015
2	Type 2 Diabetes Mellitus (MODY) 09/2015 - 06/2012
2	Rheumatoid Arthritis 03/2013 - 05/2004
2	Crohn Disease (Crohn's Disease) 01/2013 - 10/2010
1	Asthma (Bronchial Asthma) 07/2023
1	Muscular Diseases (Myopathy) 03/2023
1	Arthritis (Polyarthritis) 02/2023
1	Rheumatic Diseases (Rheumatism) 02/2023
1	IGA Glomerulonephritis (IGA Nephropathy) 05/2022
1	Unstable Angina 05/2022
1	Glomerulonephritis 04/2020
1	Albuminuria 09/2015
1	Ulcerative Colitis 01/2015
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 10/2010
1	Injection Site Reaction 05/2004
1	Neutropenia 05/2004
1	Neoplasms (Cancer) 07/2002

Drug/Important Bio-Agent (IBA)

11	avacopanIBA 02/2024 - 09/2017
8	GlucocorticoidsIBA 07/2023 - 09/2017
7	Anaphylatoxin C5a ReceptorIBA 02/2024 - 09/2017
7	Prednisone (Sone)FDA LinkGeneric 08/2023 - 09/2017
7	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 08/2023 - 01/2019
5	Chemokine ReceptorsIBA 01/2015 - 10/2010
3	Rituximab (Mabthera)FDA Link 10/2021 - 04/2020
2	AutoantibodiesIBA 02/2024 - 04/2023
2	Complement C5a (Complement 5a)IBA 03/2023 - 04/2020
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 11/2020 - 04/2020
2	CCX140-BIBA 09/2015 - 06/2012
2	LigandsIBA 01/2015 - 10/2010
2	CCX282-BIBA 01/2013 - 10/2010
1	Complement System Proteins (Complement)IBA 08/2023
1	Glucose (Dextrose)FDA LinkGeneric 03/2023
1	Azathioprine (Imuran)FDA LinkGeneric 04/2020
1	Adrenal Cortex Hormones (Corticosteroids)IBA 04/2020
1	Complement Membrane Attack Complex (Membrane Attack Complex)IBA 04/2020
1	CreatinineIBA 09/2015
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 09/2015
1	Hypoglycemic Agents (Hypoglycemics)IBA 09/2015
1	Angiotensin Receptor AntagonistsIBA 09/2015
1	AlbuminsIBA 09/2015
1	CC ChemokinesIBA 09/2015
1	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 09/2015
1	Proteins (Proteins, Gene)FDA Link 01/2015
1	C-Reactive ProteinIBA 01/2013
1	Methotrexate (Mexate)FDA LinkGeneric 05/2004
1	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 05/2004
1	Etanercept (Enbrel)FDA Link 05/2004
1	OsteoprotegerinIBA 07/2002

Therapy/Procedure

2	Remission Induction 08/2023 - 10/2021
1	Therapeutics 05/2004